second quarter 2026
Filed Aug 3, 2026Vertex Reports Second Quarter 2026 Financial Results — Total revenue of $3.33 billion, a 12% increase compared to second quarter 2025 — Raising full-year revenue guidance to $13.1 billion to $13.2 billion
Total revenue increased 12% to $3.33 billion, CASGEVY and JOURNAVX delivered substantial reported growth, and Vertex raised its full-year 2026 total revenue guidance. Cash, cash equivalents, and total marketable securities increased to $13.6 billion, although combined GAAP and non-GAAP R&D, Acquired IPR&D and SG&A expenses increased year over year.
Key metrics
as reported| Metric | Value | q/q | y/y |
|---|---|---|---|
| Total revenueother | $3.33 billion | – | 12% increase |
| U.S. total revenueother | $2.06 billion | – | 11% |
| Total revenue outside the U.S.other | $1.28 billion | – | 14% |
| Combined R&D, Acquired IPR&D and SG&A expensesGAAP | $1.6 billion | – | – |
| Combined R&D, Acquired IPR&D and SG&A expensesnon-GAAP | $1.4 billion | – | – |
| Effective tax rateGAAP | 21.0% | – | – |
| Effective tax ratenon-GAAP | 21.1% | – | – |
| Net incomeGAAP | $1.1 billion | – | – |
| Net incomenon-GAAP | $1.2 billion | – | – |
| Cash, cash equivalents, and total marketable securitiesother | $13.6 billion | – | – |
Segments
| Segment | Revenue | q/q | y/y |
|---|---|---|---|
| U.S. total revenueContinued strong CF patient demand, including from new initiations of ALYFTREK; higher realized net prices in CF versus the prior year; and contributions from CASGEVY and JOURNAVX. | $2.06 billion | – | 11% |
| Total revenue outside the U.S.Strong CF performance across multiple geographies, including ALYFTREK uptake; increased CASGEVY infusions; and a favorable impact from foreign exchange. | $1.28 billion | – | 14% |
| CASGEVYIncreased CASGEVY infusions and ongoing reimbursement progress, including reimbursement for eligible patients 12 years and older with SCD or TDT in Germany. | $76 million | 78% quarter-over-quarter sequential growth | 151% growth compared to the second quarter of 2025 |
| JOURNAVXApproximately 535,000 prescriptions were filled in the second quarter across hospital and retail settings, alongside expanded reimbursed access. | $50 million | 71% quarter-over-quarter sequential growth | more than quadrupling compared to $12 million in the second quarter of 2025 |
full year 2026 outlook
- Revenue$13.1 to $13.2 billion
- Operating expensesCombined GAAP R&D, AIPR&D and SG&A expenses of $6.3 to $6.45 billion; combined non-GAAP R&D, AIPR&D and SG&A expenses of $5.65 to $5.75 billion
- Tax rateNon-GAAP effective tax rate of 19.5% to 20.5%
- NoteNon-CF product revenue: $0.5 billion or greater
- NoteTotal revenue guidance continues to reflect a year-over-year benefit of approximately 150 basis points in growth from foreign exchange rates, net of Vertex’s foreign exchange hedging program.
- NoteThe difference between combined GAAP and non-GAAP R&D, AIPR&D and SG&A expenses guidance relates primarily to $650 million to $700 million of stock-based compensation expense.
- NoteCombined GAAP and non-GAAP R&D, AIPR&D and SG&A expenses guidance includes approximately $100 million of AIPR&D expenses.
- NoteGuidance includes an immaterial cost impact from tariffs in 2026 based on currently known tariff rates and regulations.
- NoteFinancial guidance for 2026 does not reflect the impact of the pending acquisition of Crinetics Pharmaceuticals.
Capital returns
- Repurchases of Vertex’s common stock pursuant to its share repurchase program.
What drove it
- Continued performance of cystic fibrosis therapies and growth from diversification into additional disease areas drove total revenue.
- ALYFTREK uptake contributed to U.S. and ex-U.S. revenue growth.
- Higher realized net prices in CF versus the prior year contributed to U.S. revenue growth.
- CASGEVY and JOURNAVX contributed to revenue growth.
- Commercial investment supporting the JOURNAVX launch and build-out of the renal franchise, led by povetacicept in IgAN, contributed to higher combined R&D, Acquired IPR&D and SG&A expenses.
Concerns
- Combined GAAP R&D, Acquired IPR&D and SG&A expenses increased to $1.6 billion from $1.4 billion, and combined non-GAAP expenses increased to $1.4 billion from $1.2 billion.
- GAAP and non-GAAP effective tax rates increased to 21.0% and 21.1%, respectively, from 19.5% and 19.4%, respectively.
- Financial guidance for 2026 does not reflect the impact of the pending acquisition of Crinetics Pharmaceuticals.
- Guidance includes an immaterial cost impact from tariffs in 2026 based on currently known tariff rates and regulations.
What to watch
- Vertex expects to share results from the VX-828 proof-of-concept study in the second half of 2026.
- Vertex is on track to complete enrollment in both Phase 3 studies of suzetrigine in diabetic peripheral neuropathy by the end of 2026.
- Vertex is on track to complete enrollment in a Phase 2 study of VX-993 in people with diabetic peripheral neuropathy by the end of 2026.
- Vertex continues to anticipate completion of the Crinetics Pharmaceuticals acquisition in the third quarter of 2026, subject to customary closing conditions, and will provide updated guidance for 2026 following transaction close.
- The povetacicept PDUFA date is November 30th.
Balance sheet and cash flow
- Cash, cash equivalents, and total marketable securities as of June 30, 2026, were $13.6 billion, compared to $12.3 billion as of December 31, 2025.
- The increase was primarily due to cash flows from operating activities, partially offset by repurchases of Vertex’s common stock pursuant to its share repurchase program.
Analysis
Vertex reported total revenue of $3.33 billion, a 12% increase compared to the second quarter of 2025. U.S. total revenue increased 11% to $2.06 billion, supported by CF demand, new ALYFTREK initiations, higher realized CF net prices and contributions from CASGEVY and JOURNAVX. Revenue outside the U.S. increased 14% to $1.28 billion, driven by CF performance, ALYFTREK uptake, increased CASGEVY infusions and foreign exchange.
Diversification products showed strong reported growth. CASGEVY revenue was $76 million, representing 78% quarter-over-quarter sequential growth and 151% growth compared to the second quarter of 2025. JOURNAVX revenue was $50 million, representing 71% quarter-over-quarter sequential growth and more than quadrupling compared to $12 million in the second quarter of 2025. Vertex reported approximately 535,000 JOURNAVX prescriptions filled in the second quarter and approximately 900,000 in the first six months of 2026.
Expense growth accompanied commercial and pipeline investment. Combined GAAP R&D, Acquired IPR&D and SG&A expenses were $1.6 billion, compared with $1.4 billion in the second quarter of 2025, while the non-GAAP measure was $1.4 billion, compared with $1.2 billion. GAAP net income increased to $1.1 billion from $1.0 billion, while non-GAAP net income remained $1.2 billion. Cash, cash equivalents and total marketable securities were $13.6 billion as of June 30, 2026, compared with $12.3 billion as of December 31, 2025, with operating cash flows partly offset by stock repurchases.
Vertex raised full-year 2026 total revenue guidance to $13.1 to $13.2 billion from $12.95 to $13.1 billion previously. The company reiterated expense and non-GAAP tax-rate guidance, while maintaining expectations for $0.5 billion or greater of non-CF product revenue. Guidance excludes the pending Crinetics Pharmaceuticals acquisition, which Vertex anticipates completing in the third quarter of 2026, subject to customary closing conditions.
Pipeline and access milestones remain central to the next phase of growth. Vertex expects VX-828 proof-of-concept results in the second half of 2026 and is targeting completion of enrollment in suzetrigine Phase 3 studies and VX-993 Phase 2 study by the end of 2026. The filing also identifies a November 30th PDUFA date for povetacicept and reports expanding reimbursement and regulatory activity for ALYFTREK, CASGEVY and JOURNAVX.
Management, verbatim
Vertex delivered excellent second quarter results, expanding our leadership in cystic fibrosis; delivering strong revenue growth in sickle cell disease, beta thalassemia, and acute pain; and with the pending acquisition of Crinetics, adding rare endocrine diseases as our fifth pillar, further diversifying our portfolio.
Reshma Kewalramani, M.D., Chief Executive Officer and President
Not in the filing
stated, not guessed- GAAP and non-GAAP diluted EPS
- Gross profit and gross margin
- Operating income and operating margin
- Product revenue for the cystic fibrosis portfolio
- Operating cash flow amount
- Free cash flow
- Debt balance
- Share repurchase amount and shares repurchased
- Dividend amount
- GAAP effective tax rate guidance
- Prior-quarter comparisons for total revenue, expenses, tax rates and net income
- Previous-release outlook required for vs_prior_guidance comparisons
AlphaAI analysis generated from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure was cross-checked against the filing text; consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.